Viracept AG-1343 data

Pilot Phase II results of Viracept in 30 HIV-infected patients showed significant reductions in HIV levels detectable in blood in all patients.

Subjects received one of three daily doses of a tablet formulation of AG-1343 for four weeks. Twice daily doses of 500mg, 600mg, or 750mg resulted in average maximum reductions of HIV in blood of 90 percent, 94 percent and 93 percent, respectively. ...